Corbus Pharmaceuticals announced results from its first-in-human dose escalation study of CRB-701, presented at the ASCO GU 2025 conference. This Phase 1 study assessed the efficacy and safety of ...
CRB-701 targets Nectin-4, delivering chemotherapy directly to cancer cells, minimizing damage to healthy tissue. The FDA's fast track designation aims to expedite CRB-701's development for HNSCC and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results